Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) reported early Phase 2 data for budoprutug in pMN, showing B-cell depletion, antibody reduction, and immunologic remission at 12 weeks. Both 200 mg and 600 mg doses were generally well tolerated. The company expects further data in 2027.

Climb Bio (CLYM) presented Phase 2 data for budoprutug, its anti-CD19 mAb, at ASN Kidney Week. The 200 mg dose showed B-cell depletion, PLA2R Ab reduction, and immunologic remission in pMN patients. A separate case study reported 3-year steroid-free remission in an MCD patient. Additional data is expected in 2027. The drug was generally well-tolerated.

Climb Bio (CLYM) and Beijing Mabworks reported Phase 1 data showing their anti-APRIL antibody reduced Gd-IgA1 by ~70% and IgA by ~60% at 12 weeks in healthy volunteers. The trials involved 88 participants across Australia and China. The antibody was well-tolerated, with no serious adverse events. The company plans to initiate a Phase 3 trial in 2027, pending regulatory feedback.

Climb Bio reported Phase 1 results for CLYM116, showing sustained APRIL suppression through 12 weeks and reductions in IgA and Gd-IgA1. A single dose of at least 480 mg suppressed free APRIL by 90% or more, supporting a potential every-12-week regimen. The antibody was generally well tolerated. Phase 2 trial is enrolling, with initial data expected in the first half of 2027, and a Phase 3 trial is expected to begin in 2027, pending regulatory feedback.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

Climb Bio (CLYM) and Mabworks presented Phase 1 data for CLYM116/MIL116 at ASN Kidney Week 2026, showing 90% free APRIL suppression and 70% Gd-IgA1 reduction. The drug has a 33-day half-life, supports Q12W dosing, and is generally well-tolerated. NAVIGATE-2 Phase 2 trial is enrolling, with initial data expected in 2027, and a global Phase 3 trial is planned for 2027.